DJIA 18,010.68 -115.44 -0.64%
NASDAQ 5,070.03 -27.95 -0.55%
S&P 500 2,107.39 -13.40 -0.63%
market minute promo


2.53 0.02 (0.80%)

REAL-TIME: Last trade at

Extended Hours: $2.53 $0.00 (0.00%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

VVUS $2.53 0.80%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.49
Previous Close $2.51
Daily Range $2.48 - $2.59
52-Week Range $2.22 - $5.52
Market Cap $262.7M
P/E Ratio -3.14
Dividend (Yield) $0.00 (0.0%)
Volume 1,012,650
Average Daily Volume 1,079,264
Current FY EPS -$0.83




Drug Makers

VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website:

News & Commentary Rss Feed

Orexigen Therapeutics, Inc. Goes From Biotech Beauty to Dreadful Drugmaker

A double dose of bad news for the obesity drugmaker.

Vivus's Debt Troubles And Ineffective Management

Orexigen And Takeda In Chess Match

Arena Pharmaceuticals: Hopes For Long-Term Value From Belviq Get A Lift From Congress

Vivus: Qsymia Sales Flatten Again - Third Place Out Of 3 Drugs Nothing To Celebrate

Novo Nordisk's Saxenda Delays Onset of Type II Diabetes - Analyst Blog

Orexigen: Contrave Sales Flattening - Europe Needed To Spur Numbers

Vivus: Qsymia Sales Win The Week, But Is It Enough?

Orexigen Plummets After Release Of 50% Interim Results, But Is This The End?

Why Shares of Orexigen Therapeutics, Inc. Cratered Today

Orexigen Therapeutics is crashing today following more bad news for its diet pill Contrave. Here's what investors need to know right now.

See More VVUS News...

VVUS's Top Competitors

VVUS $2.53 (0.80%)
Current stock: VVUS
JNJ $100.14 (-1.00%)
Current stock: JNJ
NVS $102.73 (-1.46%)
Current stock: NVS
RHHBY $38.46 (2.83%)
Current stock: RHHBY